Sunset at Hilton La Jolla Torrey Pines, site of the 10th Annual T-cell Lymphoma Forum; Photo by Larry Young

The 10th Annual T-cell Lymphoma Forum took place Feb. 1-3, 2018, in La Jolla, California.

Antibody has ‘very promising activity’ in rel/ref CTCL

Print Friendly, PDF & Email


Youn H. Kim, MD
Photo by Larry Young
An antibody targeting KIR3DL2 has “very promising activity” in relapsed/refractory cutaneous T-cell lymphoma (CTCL), according to a speaker at the 10th Annual T-cell Lymphoma Forum. The antibody, IPH4102, produced an overall response rate (ORR) of 44% in a phase 1 trial of CTCL patients, with an... [Read Article]
Print Friendly, PDF & Email

Drug appears safe and active in PTCL, CTCL

Print Friendly, PDF & Email


Bradley M. Haverkos, MD
Photo by Larry Young
The dual PI3K δ/γ inhibitor tenalisib has demonstrated activity in a phase 1 trial of patients with relapsed/refractory T-cell lymphomas. Tenalisib produced “encouraging” response rates of 44% in patients with cutaneous T-cell lymphoma (CTCL) and 50% in patients with peripheral T-cell lymphoma (PTCL), according to... [Read Article]
Print Friendly, PDF & Email

FDG PET can’t replace BM biopsy, study suggests

Print Friendly, PDF & Email


Youngil Koh, MD
Photo by Larry Young
Fluorodeoxyglucose positron emission tomography (FDG PET) cannot replace bone marrow (BM) biopsy in T-cell lymphomas, according to a speaker at the 10th Annual T-cell Lymphoma Forum. Researchers found that FDG PET results did not exactly correlate with BM biopsy results relating to tumor involvement in patients... [Read Article]
Print Friendly, PDF & Email

Inhibitor provides clinical improvement in MF

Print Friendly, PDF & Email


Christiane Querfeld, MD, PhD
Photo by Larry Young
Results of a phase 1 trial suggest MRG-106 can provide clinical improvement in patients with mycosis fungoides (MF), whether the drug is given alone or in conjunction with other therapies. MRG-106 is an inhibitor of microRNA-155, which is upregulated in MF. In this ongoing trial, 90%... [Read Article]
Print Friendly, PDF & Email

Drug may be option for B- and T-cell lymphomas

Print Friendly, PDF & Email


Session at the 10th Annual
T-cell Lymphoma Forum
Photo by Larry Young
The EZH1/2 inhibitor DS-3201b could be a novel therapeutic option for non-Hodgkin lymphoma (NHL), according to a speaker at the 10th Annual T-cell Lymphoma Forum. DS-3201b was considered well tolerated in a phase 1 study of Japanese patients with relapsed/refractory NHL.... [Read Article]
Print Friendly, PDF & Email

Favorable results with chidamide in rel/ref NKTCL

Print Friendly, PDF & Email


Huiqiang Huang, MD, PhD
Photo by Larry Young
Results of a phase 2 study suggest chidamide can produce durable responses in patients with relapsed/refractory natural killer/T-cell lymphoma (NKTCL). The overall response rate was 57.2% in these patients, and the complete response (CR) rate was 28.6%. Seven of 14 evaluable patients were still receiving chidamide... [Read Article]
Print Friendly, PDF & Email

Combo is preferentially active in T-cell lymphomas

Print Friendly, PDF & Email


Lorenzo Falchi, MD
Photo by Larry Young
A 2-drug combination has demonstrated preferential activity in T-cell lymphomas over B-cell lymphomas, according to researchers. In a small, phase 1/2 study, treatment with oral 5-azacitidine and romidepsin produced a higher overall response rate (ORR) and prolonged progression-free survival (PFS) in patients with T-cell lymphomas. “In... [Read Article]
Print Friendly, PDF & Email

Duvelisib combos show promise for PTCL, CTCL

Print Friendly, PDF & Email


Poster reception
at the 10th Annual
T-cell Lymphoma Forum
Photo by Larry Young
Phase 1 results suggest duvelisib combination therapies can be active and well-tolerated in patients with relapsed/refractory T-cell lymphomas. Researchers said duvelisib had an acceptable safety profile when given in combination with romidepsin or bortezomib to patients with relapsed/refractory peripheral T-cell... [Read Article]
Print Friendly, PDF & Email

Mogamulizumab is ‘valuable’ option for CTCL

Print Friendly, PDF & Email


Youn H. Kim, MD
Photo by Larry Young
Mogamulizumab is a valuable new therapeutic option for patients with cutaneous T-cell lymphoma (CTCL), according to researchers. Results of the phase 3 MAVORIC study indicated that mogamulizumab is more effective than vorinostat in previously treated patients with CTCL. Mogamulizumab produced a better overall response rate (ORR)... [Read Article]
Print Friendly, PDF & Email